Claims
- 1. A method of determining a prognosis, comprising:
a) providing a blood sample from a subject, wherein said blood sample comprises neutrophils, and wherein said subject is diagnosed with sepsis; and b) detecting the level of expression of C5aR on said neutrophils.
- 2. The method of claim 1, wherein an increased level of expression of said C5aR on said neutrophils relative to a normal standard is indicative of an increased rate of survival of said subject.
- 3. The method of claim 1, wherein a decreased level of expression of said C5aR on said neutrophils relative to a normal standard is indicative of a decreased rate of survival of said subject.
- 4. The method of claim 1, wherein said detecting the level of expression of C5aR on said neutrophils comprises exposing said blood sample to an anti-C5aR antibody.
- 5. The method of claim 4, wherein said antibody is labeled with a fluorescent label.
- 6. The method of claim 5, wherein said detecting the level of expression of C5aR on said neutrophils further comprises subjecting said blood sample to fluorescence activated cell sorting.
- 7. The method of claim 1, wherein said method is completed in one hour or less.
- 8. The method of claim 1, wherein said blood sample comprises 100 μl or less of blood.
- 9. A method of screening compounds, comprising
a) providing
i) a neutrophil, wherein said neutrophil expresses C5aR; and ii) one or more test compounds; and b) contacting said neutrophil with said test compound; and c) detecting the level at which said neutrophil expresses said C5aR.
- 10. The method of claim 9, wherein said neutrophil expresses more of said C5aR in the presence of said test compound than in the absence of said test compound.
- 11. The method of claim 9, wherein said detecting the level of expression of C5aR on said neutrophils comprises exposing said blood sample to an anti-C5aR antibody.
- 12. The method of claim 11, wherein said antibody is labeled with a fluorescent label.
- 13. The method of claim 12, wherein said detecting the level of expression of C5aR10n said neutrophils further comprises subjecting said blood sample to fluorescence activated cell sorting.
- 14. The method of claim 10, wherein said cell is in a host.
- 15. The method of claim 14, wherein said host has been diagnosed with sepsis.
- 16. The method of claim 14, wherein said host is a non-human animal.
- 17. The method of claim 16, wherein said non-human animal is an animal model of sepsis.
- 18. The method of claim 9, wherein said test compound is an anti-C5aR antibody.
- 19. The method of claim 9, wherein said test compound is a C5aR antagonist.
- 20. A kit for providing a prognosis to a subject diagnosed with sepsis, comprising
a) a reagent for determining the level of C5aR expression on a neutrophil; and b) instructions for using said reagent for providing a prognosis to said subject.
- 21. The kit of claim 20, wherein said reagent is an anti-C5aR antibody.
- 22. The kit of claim 21, wherein said antibody is labeled with a fluorescent label.
- 23. The kit of claim 22, wherein said kit further comprises reagents for using fluorescence activated cell sorting to detect said antibody.
- 24. The kit of claim 20, further comprising a normal standard for C5aR expression.
- 25. The kit of claim 24, further comprising instructions for using said normal standard for quantitating the level of C5aR expression on neutrophils of said subject.
- 26. A method of treating sepsis, comprising
a) providing a reagent capable of blocking a C5a receptor; and b) administering said reagent to a subject suffering from sepsis.
- 27. The method of claim 26, wherein said administering results in a decrease in symptoms of sepsis in the subject.
- 28. The method of claim 26, wherein said reagent is a small molecule antagonist of the C5a receptor.
- 29. The method of claim 28, wherein said small molecule antagonist is selected from the group consisting of F[OPdChaWR] and MeFKPdChaFR.
- 30. The method of claim 26, wherein said is an antibody specific for the C5a receptor.
Parent Case Info
[0001] This application claims priority to provisional patent application serial No. 60/423,759, filed Nov. 5, 2002, which is herein incorporated by reference in its entirety.
Government Interests
[0002] This invention was made with Government support under the National Institutes of Health (NIH) awarded by contracts GM61656-01, GM-29507, and HL-31963. The government may have certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60423759 |
Nov 2002 |
US |